Here's Why Fresenius (FMS) Looks Ripe for Bottom Fishing
Fresenius (FMS) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a trend reversal for the stock in the near term.
Here's Why Fresenius (FMS) is a Strong Value Stock
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Is the Options Market Predicting a Spike in Fresenius Medical Stock?
Investors need to pay close attention to FMS stock based on the movements in the options market lately.
Fresenius Medical Care: Is Trading Below Its Intrinsic Value (Buy)
Fresenius Medical Care (FMS) is rated a buy, with shares up 32.95% YoY and strong Q1 2025 results, showing 60% (YoY) net income growth. My valuation using a forward P/S ratio suggests FMS is undervalued by over 130%, with a projected share price of $62.06 by 2026. Compared to peers, FMS offers the highest potential upside and a superior 3.07% dividend yield, making it an attractive value play.
Why Fresenius (FMS) is a Top Value Stock for the Long-Term
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Reasons to Add Fresenius Medical Stock to Your Portfolio Now
FMS continues to gain traction on the back of acquisitions & partnerships. A tough regulatory environment raises concerns.
FMS vs. RXST: Which Stock Is the Better Value Option?
Investors looking for stocks in the Medical - Instruments sector might want to consider either Fresenius (FMS) or RxSight, Inc. (RXST). But which of these two companies is the best option for those looking for undervalued stocks?
FMS Stock Likely to Gain on New Optimization Plan FME Reignite
Fresenius Medical Care unveils FME Reignite, targeting one billion euros in cost savings, tech upgrades and enhanced shareholder returns.
FMS or RXST: Which Is the Better Value Stock Right Now?
Investors looking for stocks in the Medical - Instruments sector might want to consider either Fresenius (FMS) or RxSight, Inc. (RXST). But which of these two companies is the best option for those looking for undervalued stocks?
Fresenius Medical Care announces 1 bln euros share buyback programme
The world's largest dialysis specialist Fresenius Medical Care said, ahead of its capital markets day on Tuesday, that it plans to embark on a 1 billion euros ($1.16 billion) share buyback programme.
Reasons to Add Fresenius Medical Stock to Your Portfolio Now
FMS continues to gain traction on the back of acquisitions & partnerships. A tough regulatory environment raises concerns.
Fresenius (FMS) Upgraded to Buy: Here's Why
Fresenius (FMS) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
